Subscribe
shutterstock_1635580639_sundry_photography
Sundry Photography / Shutterstock.com
8 July 2021GenericsRory O'Neill

Taiwanese biotech built on ‘foundation of lies’, says DoJ

US prosecutors have charged the founders of Taiwanese biosimilar manufacturer JHL Biotech with stealing  Genentech trade secrets.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Genentech to face revived Hemlibra claims
28 August 2020   Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta.
Biotechnology
English court sides with Eli Lilly in Genentech jurisdictional clash
8 December 2017   The English High Court has sided with Eli Lilly in holding that its UK-related claims in a patent case can be heard together with its European-based arguments in the UK.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Big Pharma
Genentech to face revived Hemlibra claims
28 August 2020   Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta.
Biotechnology
English court sides with Eli Lilly in Genentech jurisdictional clash
8 December 2017   The English High Court has sided with Eli Lilly in holding that its UK-related claims in a patent case can be heard together with its European-based arguments in the UK.

More on this story

Big Pharma
Genentech to face revived Hemlibra claims
28 August 2020   Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta.
Biotechnology
English court sides with Eli Lilly in Genentech jurisdictional clash
8 December 2017   The English High Court has sided with Eli Lilly in holding that its UK-related claims in a patent case can be heard together with its European-based arguments in the UK.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims